Education
About Us
Working with TipRanks
Follow Us
Iovance Biotherapeutics Inc (IOVA)
NASDAQ:IOVA
Top Page
Iovance Biotherapeutics
(NASDAQ:IOVA)
48Neutral
Positive Factors
Product Demand
Strong Proleukin sales indicate rapid and sustained demand for AMTAGVI, suggesting potential growth in the upcoming year.
Revenue Guidance
Management reiterated 2025 revenue guidance of $450-475MM, which will be driven by continued expansion within ATCs.
Sales Growth
Proleukin revenues in 4Q24 were $25.0MM due to the activation and subsequent stocking of a third specialty distributor, with management expecting demand to continue growing.
Negative Factors
Revenue Expectations
4Q24 revenues from Amtagvi were lower than both the analyst's and consensus estimates.
Revenue Miss
Q4 Amtagvi revenue of $49MM missed consensus of $55MM by 11%.
Revenue Performance
The stock is down approximately 20% post-close because of perceived Amtagvi revenue slowdown.
Iovance Biotherapeutics (IOVA) vs. S&P 500 (SPY)
Market Cap
$1.18B
Dividend YieldN/A
Average Volume (3M)9.33M
Price to Earnings (P/E)―
Beta (1Y)2.28
Revenue Growth13698.99%
EPS Growth31.46%
CountryUS
Employees838
SectorHealthcare
Sector Strength70
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.30
Shares Outstanding327,876,700
10 Day Avg. Volume8,691,958
30 Day Avg. Volume9,334,030
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.68
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit49.67
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$18.17Price Target Upside406.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Iovance Biotherapeutics Business Overview & Revenue Model
Company DescriptionIovance Biotherapeutics, Inc. is a biotechnology company focused on the development and commercialization of novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology. The company operates within the biotechnology and pharmaceuticals sectors, primarily targeting various forms of cancer. Iovance's core product candidates include lifileucel for the treatment of metastatic melanoma and LN-145 for the treatment of cervical cancer and other solid tumors.
How the Company Makes MoneyIovance Biotherapeutics generates revenue through the development and potential commercialization of its TIL-based therapies. The company's revenue model is centered around the successful clinical development and eventual approval of its product candidates, which would allow it to earn revenue through direct sales, partnerships, and collaborations with other pharmaceutical companies. Key revenue streams are anticipated from the commercialization of lifileucel and LN-145, pending regulatory approvals. Iovance may also engage in licensing agreements and collaborations with other biotechnology and pharmaceutical companies, which can provide upfront payments, milestone payments, and royalties. Additionally, the company may receive funding through partnerships or grants that support its research and development activities.
Iovance Biotherapeutics Financial Statement Overview
Summary
Iovance Biotherapeutics is experiencing robust revenue growth with a significant increase in revenue from $1.19 million to $164.07 million. However, profitability remains a major concern as evidenced by negative EBIT and net income margins. The balance sheet shows a stable financial structure with low leverage, but continuous operating losses and significant cash burn highlight financial challenges.Income Statement
Iovance Biotherapeutics has shown significant revenue growth from $1.19 million in 2023 to $164.07 million in 2024, marking a substantial increase. However, the company is still struggling with profitability, as evidenced by negative EBIT and net income margins. The gross profit margin has improved to 24.42%, but the net profit margin remains deeply negative at -226.83%, indicating ongoing challenges in achieving overall profitability.40
Negative
Balance Sheet
The company's balance sheet shows a strong equity position with a debt-to-equity ratio of 0.08, which indicates low financial leverage. Stockholders' equity has grown to $710.41 million, and the equity ratio stands at 78.05%, demonstrating a stable financial structure. However, the company continues to operate with significant net losses, which could impact equity over time.55
Neutral
Cash Flow
Iovance Biotherapeutics has a negative free cash flow of -$364.05 million, which has slightly improved from the previous year. The operating cash flow to net income ratio is slightly negative, reflecting ongoing cash burn challenges. The company has been relying heavily on financing activities to support cash requirements, which may not be sustainable long-term.35
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 164.07M | 1.19M | 0.00 | 0.00 | 0.00 | Gross Profit |
| 40.08M | -9.57M | -21.14M | -13.98M | -8.71M | EBIT |
| -395.28M | -460.56M | -398.88M | -342.70M | -261.94M | EBITDA |
| -395.28M | -427.43M | -374.76M | -328.27M | -250.87M | Net Income Common Stockholders |
| -372.18M | -444.04M | -389.92M | -327.82M | -257.23M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 323.78M | 279.87M | 471.85M | 596.00M | 629.44M | Total Assets |
| 910.43M | 780.35M | 663.98M | 777.33M | 768.46M | Total Debt |
| 57.26M | 75.86M | 84.45M | 71.53M | 51.66M | Net Debt |
| -58.43M | -39.03M | -147.28M | -6.70M | -15.67M | Total Liabilities |
| 200.02M | 195.74M | 164.34M | 155.67M | 111.96M | Stockholders Equity |
| 710.40M | 584.61M | 499.64M | 621.66M | 656.50M |
| Cash Flow | Free Cash Flow | |||
| -364.05M | -384.11M | -313.18M | -265.51M | -251.93M | Operating Cash Flow |
| -352.98M | -361.82M | -292.76M | -227.94M | -205.13M | Investing Cash Flow |
| -96.41M | -155.24M | 256.45M | 132.00K | -317.85M | Financing Cash Flow |
| 390.66M | 462.96M | 190.15M | 239.27M | 576.42M |
Iovance Biotherapeutics Technical Analysis
Neutral
3.59
Price Trends
3.77
Negative
5.28
Negative
7.54
Negative
Market Momentum
-0.06
Negative
53.73
Neutral
90.89
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IOVA, the sentiment is Neutral. The current price of 3.59 is above the 20-day moving average (MA) of 3.26, below the 50-day MA of 3.77, and below the 200-day MA of 7.54, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 53.73 is Neutral, neither overbought nor oversold. The STOCH value of 90.89 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IOVA.
Iovance Biotherapeutics Risk Analysis
Iovance Biotherapeutics disclosed 81 risk factors in its most recent earnings report. Iovance Biotherapeutics reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Iovance Biotherapeutics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $1.24B | ― | -12.08% | ― | 3.85% | -339.15% | |
57 Neutral | $1.28B | ― | -23.01% | ― | 168.06% | 44.66% | |
52 Neutral | $5.38B | 3.59 | -41.63% | 2.87% | 17.72% | 1.87% | |
48 Neutral | $1.18B | ― | -57.48% | ― | 13698.99% | 31.46% | |
48 Neutral | $1.22B | ― | -75.69% | ― | ― | -25.83% | |
46 Neutral | $1.08B | ― | -78.34% | ― | ― | -70.45% | |
41 Neutral | $1.11B | ― | -45.77% | ― | -3.82% | 29.10% |
* Healthcare Sector Average
Performance Comparison
IOVA
Iovance Biotherapeutics
3.59
-8.91
-71.28%
PCRX
Pacira Pharmaceuticals
26.90
-0.05
-0.19%
ARDX
Ardelyx
5.50
-1.11
-16.79%
VRDN
Viridian Therapeutics
13.55
-0.26
-1.88%
SNDX
Syndax Pharmaceuticals
14.15
-7.82
-35.59%
ETNB
89bio
8.02
-0.73
-8.34%
Iovance Biotherapeutics Earnings Call Summary
Earnings Call Date:Feb 27, 2025
(Q4-2024)
| % Change Since: -31.75%|
Next Earnings Date:May 13, 2025
Earnings Call Sentiment Positive
The earnings call demonstrated strong revenue performance and positive market adoption for Amtagvi, with significant highlights in manufacturing capacity and pipeline progress. However, high operating costs and the need for acceleration in adoption at ATCs present challenges.Q4-2024 Updates
Positive Updates
Strong Revenue Performance
Total product revenue reached $73.7 million in Q4 and $164.1 million for the full year 2024, achieving the upper end of guidance. Amtagvi generated $103.6 million, and Proleukin earned $60.5 million for the year.
Positive Market Adoption
Over 200 patients treated with Amtagvi in its first year. 70 authorized treatment centers (ATCs) are active, covering 32 states, with over 95% of U.S. lives having reimbursement access.
Manufacturing Capacity and Expansion
Current manufacturing capacity can support over 1,200 patients annually, with plans to expand to over 5,000 patients in the future.
Pipeline and Regulatory Progress
U.S. and global expansion plans for Amtagvi are on track, with potential approvals in the UK, Canada, and the EU in 2025. Ongoing trials for advanced melanoma and non-small cell lung cancer show promise.
Negative Updates
High Operating Costs
Cost of sales for the year totaled $124 million, with significant expenses for patient drop-off and manufacturing success rates, which impacted gross margin.
Challenges in Adoption Acceleration
While there is strong initial uptake, a significant portion of ATCs have yet to reach a steady state of patient infusions, suggesting room for growth but also current limitations in adoption.
Company Guidance
In the Iovance Biotherapeutics fourth quarter and full year 2024 financial results conference call, the company reported a total product revenue of $73.7 million for Q4 and $164.1 million for the full year, meeting the upper end of their guidance range of $160 million to $165 million. The revenue comprised $48.7 million from Amtagvi and $25.0 million from Proleukin in Q4, with full year figures at $103.6 million and $60.5 million, respectively. Iovance treated over 200 patients with Amtagvi in its partial first year of launch. The guidance for 2025 is set at $450 million to $475 million in total product revenue, driven by anticipated growth in both Amtagvi and Proleukin sales. The company has a staffed capacity to supply over 1,200 patients annually and aims to expand its network of authorized treatment centers (ATCs) to meet increasing demand. The gross margin for Q4 improved significantly and is on track to surpass 70% in the coming years, while cash burn is expected to decrease, further supporting the company's path toward profitability.Iovance Biotherapeutics Corporate Events
Business Operations and Strategy
Iovance Biotherapeutics Optimizes Headquarters for Cost Efficiency
Neutral
Nov 21, 2024
Iovance Biotherapeutics is set to relocate its headquarters within the same building in San Carlos, California, opting for a smaller space to reduce costs amid an increase in remote work. The new lease significantly lowers their monthly rent from $279,540.80 to an initial $99,549.53, reflecting the company’s strategic cost-cutting measures. This move follows the termination of their previous lease for a larger space, highlighting their focus on financial efficiency.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.